Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Laboratory study: Scientists from Cologne explore a new approach to prevent newborn epilepsies

24.11.2015

Specific forms of epilepsy may manifest as early as in the first weeks of life. A new laboratory study shows that a preventive therapeutic strategy can be successful if it is applied within a time window critical to brain development. The study, which was conducted by a team of German and French scientists and headed by Prof. Dirk Isbrandt of the German Center for Neurodegenerative Diseases (DZNE) and the University of Cologne, has just been published in Nature Medicine.

Using the substance bumetanide in newborn mice, the scientists succeeded in attenuating the disease progression, allowing the animals to develop almost normally. These research results could pave the way for the development of new therapeutic strategies in humans.


This sequence of images shows individual neurons in the background (cell nuclei are blue colored). The traces in the foreground illustrate electrical activity of individual neurons. Kv7 potassium channel dysfunction results in hyperactivity of neurons manifesting in a rapid succession of action potential bursts. Image: DZNE/Stephan Marguet and Malte Stockebrand

Isbrandt and his colleagues conducted experiments in mice with a genetic defect similar to a natural human variant that can cause epilepsy as early as the neonatal period. This mutation results in dysfunctional ion channels in the membranes of nerve cells, thus perturbing the communication between cells.

Possible symptoms include jerking or twitching movements, but can also include more subtle behavioral impairments. Early disease symptoms can be mild, but long-term outcomes may be severe, and include pronounced cognitive impairment.

'This genetic defect has an impact on a specific ion channel in the cell membrane, the so-called Kv7 or M channel. The defect disturbs the ionic balance, which has a direct effect on the excitability of neurons’, explains Isbrandt, who is a researcher for the DZNE and who also holds a professorship for Experimental Neurophysiology at the University of Cologne.

'Epilepsy in newborns, for example, can be caused by hypoxia, hemorrhage, or infections. In the absence of birth injuries, Kv7-channel mutations, or other ion channel mutations, are often an underlying cause. There are hardly any efficacious therapies for these patients.’

Studies in mice

Isbrandt and his colleagues had previously discovered that the Kv7 channel is especially important for early brain development. Isbrandt says, ‘In newborn mice, the first two postnatal weeks are of critical importance, whereas in adult mice, the physiology of the brain has changed to the point where this channel plays a less prominent role.’

At this stage, that is, for the first two weeks of life, the scientists treated mice carrying a mutation of the Kv7 channel using the substance ‘bumetanide’, which has previously been shown to help neurons mantaining their ionic balance. Surprisingly, bumetanide turned out to be even more efficacious than expected, and the later disease symptoms of early Kv7 ion channel dysfunction were almost completely prevented.

The right timing

Treatment within the two-week neonatal period normalized the brain activity of mice and, to a large extent, also their behavior. No epileptic seizures occurred in the adult period, in spite of the continued presence of the genetic defect. ‘The two-week therapy almost completely prevented the consequences of Kv7 channel deficiency, because we treated the mice at a defined period critical to brain development’, summarizes Isbrandt.

Unlike mice treated with bumetanide within this time window, their littermates carrying the same genetic defect developed epilepsy. Both brain activity and structure were altered. In addition, the affected animals displayed hyperactivity and other behavioral abnormalities.

Potential therapeutic approach in humans

In adult patients, bumetanide is used for the treatment of kidney and heart diseases. There are also trials studying the treatment of epileptic seizures in newborns with bumetanide. However, these studies are aimed at the attenuation of acute symptoms, not at long-term disease prevention.

‘Our goal was to show whether prevention can in principle work. Our study demonstrates the right timing is of the essence’, says Isbrandt. ‘These results therefore underscore a strategic approach, which is to identify the period critical to a disease’s development during which treatment will have the maximum preventive power.’

‘In mice, the first two postnatal weeks approximately correspond to the last trimester of pregnancy in humans’, explains Isbrandt. ‘Thus, therapeutic treatment for related human conditions would presumably have to start in the womb, but currently this approach is far-fetched. A more immediate approach would be to treat premature babies known to be at high risk for the development of epilepsies, but it has yet to be determined whether such an intervention can be implemented.’

This research was supported by grants from the Federal Ministry of Education and Research (BMBF) as part of the research program „NGFN-Plus“, and by the German Research Foundation (DFG).

Original publication
„Treatment during a vulnerable developmental period rescues a genetic epilepsy“, Stephan Lawrence Marguet, Vu Thao Quyen Le-Schulte, Andrea Merseburg, Axel Neu, Ronny Eichler, Igor Jakovcevski, Anton Ivanov , Ileana Livia Hanganu-Opatz, Christophe Bernard, Fabio Morellini, Dirk Isbrandt, Nature Medicine, DOI: 10.1038/nm.3987

Weitere Informationen:

http://www.dzne.de/en/about-us/public-relations/meldungen/2015/press-release-no-...

Dr. Marcus Neitzert | idw - Informationsdienst Wissenschaft

Further reports about: Treatment animals disease symptoms epileptic seizures humans newborn

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>